Performance of different imaging modalities in assessment of response to neoadjuvant therapy in primary esophageal cancer

Ferlay, 2010, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 127, 2893, 10.1002/ijc.25516

Allum, 2009, Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer, J Clin Oncol, 27, 5062, 10.1200/JCO.2009.22.2083

Ychou, 2011, Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial, J Clin Oncol, 29, 1715, 10.1200/JCO.2010.33.0597

Sjoquist, 2011, Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis, Lancet Oncol, 12, 681, 10.1016/S1470-2045(11)70142-5

Hagen, 2012, Preoperative chemoradiotherapy for esophageal or junctional cancer, N Engl J Med, 366, 2074, 10.1056/NEJMoa1112088

Kelsen, 2007, Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer, J Clin Oncol, 25, 3719, 10.1200/JCO.2006.10.4760

Kim, 2009, Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy, Radiographics, 29, 403, 10.1148/rg.292085106

Lightdale, 2005, Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer, J Clin Oncol, 23, 4483, 10.1200/JCO.2005.20.644

Parmar, 2002, Clinical impact of endoscopic ultrasound-guided fine needle aspiration of celiac axis lymph nodes (M1a disease) in esophageal cancer, Ann Thorac Surg, 73, 916, 10.1016/S0003-4975(01)03560-3

Kalaitzakis, 2009, Controversies in the use of endoscopic ultrasound in esophageal cancer staging, Scand J Gastroenterol, 44, 133, 10.1080/00365520802273066

Westerterp, 2005, Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review, Radiology, 236, 841, 10.1148/radiol.2363041042

Griffin, 2012, Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer, Ann Thorac Surg, 93, 1855, 10.1016/j.athoracsur.2011.12.095

Willis, 2002, Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma, Gastrointest Endosc, 55, 655, 10.1067/mge.2002.123273

Mesenas, 2008, A large series, resection controlled study to assess the value of radial EUS in restaging gastroesophageal cancer following neoadjuvant chemotherapy, Dis Esophagus, 21, 37, 10.1111/j.1442-2050.2007.00731.x

Schneider, 2008, Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer, Ann Surg, 248, 902, 10.1097/SLA.0b013e31818f3afb

Laterza, 1999, Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy, Ann Thorac Surg, 67, 1466, 10.1016/S0003-4975(99)00267-2

Cerfolio, 2005, The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy, J Thorac Cardiovasc Surg, 129, 1232, 10.1016/j.jtcvs.2004.12.042

Kroep, 2003, Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods, Mol Imaging Biol, 5, 337, 10.1016/j.mibio.2003.09.007

Isenberg, 1998, Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation, Gastrointest Endosc, 48, 158, 10.1016/S0016-5107(98)70157-9

Hirata, 1997, Using endosonography to assess the effects of neoadjuvant therapy in patients with advanced esophageal cancer, AJR Am J Roentgenol, 169, 485, 10.2214/ajr.169.2.9242759

Jost, 2010, Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase II study by the Swiss Group for Clinical Cancer Research (SAKK 75/02), Gastrointest Endosc, 71, 1114, 10.1016/j.gie.2009.12.015

Vliet, 2006, Staging of esophageal carcinoma in a low-volume EUS center compared with reported results from high-volume centers, Gastrointest Endosc, 63, 938, 10.1016/j.gie.2006.01.053

Beer, 2006, Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy, Radiology, 239, 472, 10.1148/radiol.2391050043

Heijl, 2011, Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer, Eur J Surg Oncol, 37, 1064, 10.1016/j.ejso.2011.09.004

Griffith, 1999, Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT, Br J Radiol, 72, 678, 10.1259/bjr.72.859.10624325

Jones, 1999, Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy, Cancer, 85, 1026, 10.1002/(SICI)1097-0142(19990301)85:5<1026::AID-CNCR3>3.0.CO;2-N

Swisher, 2004, Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer, Ann Thorac Surg, 78, 1152, 10.1016/j.athoracsur.2004.04.046

Konieczny, 2013, Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer, Eur Radiol, 23, 2492, 10.1007/s00330-013-2844-8

Shankar, 2006, Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials, J Nucl Med, 47, 1059

Wieder, 2007, Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction, Eur J Nucl Med Mol Imaging, 34, 1925, 10.1007/s00259-007-0521-3

Weber, 2001, Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging, J Clin Oncol, 19, 3058, 10.1200/JCO.2001.19.12.3058

Ott, 2003, Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial, J Clin Oncol, 21, 4604, 10.1200/JCO.2003.06.574

Lordick, 2007, PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial, Lancet Oncol, 8, 797, 10.1016/S1470-2045(07)70244-9

Buschenfelde, 2011, (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial, J Nucl Med, 52, 1189, 10.2967/jnumed.110.085803

Malik, 2010, Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus, J Nucl Med, 51, 1863, 10.2967/jnumed.110.079566

Gillham, 2006, (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response, Br J Cancer, 95, 1174, 10.1038/sj.bjc.6603412

Flamen, 2002, Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer, Ann Oncol, 13, 361, 10.1093/annonc/mdf081

Higuchi, 2008, Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma, J Thorac Cardiovasc Surg, 136, 205, 10.1016/j.jtcvs.2008.02.016

Song, 2005, FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer, Int J Radiat Oncol Biol Phys, 63, 1053, 10.1016/j.ijrobp.2005.03.033

Levine, 2006, Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer, Ann Surg, 243, 472, 10.1097/01.sla.0000208430.07050.61

Arslan, 2002, Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer, Mol Imaging Biol, 4, 301, 10.1016/S1536-1632(02)00011-2

Bruzzi, 2007, Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy, Cancer, 109, 125, 10.1002/cncr.22397

McLoughlin, 2008, Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?, J Am Coll Surg, 206, 879, 10.1016/j.jamcollsurg.2007.12.027

Port, 2007, Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma, Ann Thorac Surg, 84, 393, 10.1016/j.athoracsur.2007.03.094

Chen, 2011, Can (1)(8)F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis, Nucl Med Commun, 32, 1005, 10.1097/MNM.0b013e32834a8366

Rebollo Aguirre, 2009, 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature, Ann Surg, 250, 247, 10.1097/SLA.0b013e3181b0c3a6

Kim, 2007, Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy, Eur J Cancer, 43, 1385, 10.1016/j.ejca.2007.04.001

Choyke, 2003, Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging, J Magn Resonan Imaging, 17, 509, 10.1002/jmri.10304

Turkbey, 2009, Imaging of tumor angiogenesis: functional or targeted?, AJR Am J Roentgenol, 193, 304, 10.2214/AJR.09.2869

Langen, 2008, Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow, Oncologist, 13, 631, 10.1634/theoncologist.2007-0235

Tofts, 1999, Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols, J Magn Resonan Imaging, 10, 223, 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S

Jain, 2013, Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers, J Clin Oncol, 31, 2205, 10.1200/JCO.2012.46.3653

Fenton, 2001, Effects of radiation on tumor intravascular oxygenation, vascular configuration, development of hypoxia, and clonogenic survival, Radiat Res, 155, 360, 10.1667/0033-7587(2001)155[0360:EOROTI]2.0.CO;2

Moeller, 2004, Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules, Cancer Cell, 5, 429, 10.1016/S1535-6108(04)00115-1

Padhani, 2007, Imaging oxygenation of human tumours, Eur Radiol, 17, 861, 10.1007/s00330-006-0431-y

Krohn, 2008, Molecular imaging of hypoxia, J Nucl Med, 49, 129S, 10.2967/jnumed.107.045914

Koh, 2007, Diffusion-weighted MRI in the body: applications and challenges in oncology, AJR Am J Roentgenol, 188, 1622, 10.2214/AJR.06.1403

Heijmen, 2012, Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use?, Crit Rev Oncol Hematol, 83, 194, 10.1016/j.critrevonc.2011.12.008

Hagmann, 2006, Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond, Radiographics, 26, S205, 10.1148/rg.26si065510

Aoyagi, 2011, Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer, Dig Surg, 28, 252, 10.1159/000328770

Oberholzer, 2008, Assessment of tumor microcirculation with dynamic contrast-enhanced MRI in patients with esophageal cancer: initial experience, J Magn Resonan Imaging, 27, 1296, 10.1002/jmri.21305

Weber, 2013, Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction, J Gastrointestin Liver Dis, 22, 45

De Cobelli, 2013, Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology, Eur Radiol, 23, 2165, 10.1007/s00330-013-2807-0

Davnall, 2012, Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?, Insights Imaging, 3, 573, 10.1007/s13244-012-0196-6

Yip, 2014, Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy, Radiology, 270, 141, 10.1148/radiol.13122869

Yip, 2014, Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer, Dis Esophagus

Ganeshan, 2012, Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival, Clin Radiol, 67, 157, 10.1016/j.crad.2011.08.012

Tixier, 2011, Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer, J Nucl Med, 52, 369, 10.2967/jnumed.110.082404